Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of a transaction involving a Person Discharging Managerial Responsibility (PDMR) in accordance with the Disclosure and Transparency Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding a specific executive transaction rather than a financial results report.
Material Changes
The filing details a change in the interests of Mrs. V A Whyte, the Company Secretary. Following the vesting of 50% of an award made on July 8, 2010, under the GlaxoSmithKline Deferred Investment Award Plan, she is scheduled to receive a cash payment of 1,563.75 pence per share in respect of 6,836.618 notional Ordinary shares on July 18, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific executive compensation event described.
Investor Verification Points
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Plan.
- Confirm the total cash payout amount for Mrs. V A Whyte based on the share price at the time of payment.
- Review the company's broader executive compensation policies for similar deferred investment awards.